Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Methylfenidaat bij overlevenden van pediatrische hersentumor met kankergerelateerde vermoeidheid (EMBRAIN)

30 oktober 2026 bijgewerkt door: Odense University Hospital

Effect van methylfenidaat op kankergerelateerde vermoeidheid bij patiënten die tijdens de kindertijd of adolescentie werden behandeld voor een hersentumor: protocol voor een gerandomiseerde, dubbelblinde, placebo-gecontroleerde crossover-studie-de omarmingstudie

Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking.

The researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit/hyperactivity disorder (ADHD).

If methylphenidate shows an effect, the prospects are important for this patient group, since methylphenidate may then be included as part of the treatment of brain tumor-related fatigue.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

50

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

      • Aalborg, Denemarken, 9000
        • Werving
        • Aalborg University Hospital
        • Contact:
          • Christina Friis Jensen, Consultant, MD
          • Telefoonnummer: +45 97663368
          • E-mail: cfj@rn.dk
        • Hoofdonderzoeker:
          • Christina Friis Jensen, Consultant, MD
      • Aarhus, Denemarken, 8200
        • Werving
        • Aarhus University Hospital
        • Contact:
          • Louise T Henriksen, MD, PhD
          • Telefoonnummer: +45 20921611
          • E-mail: louhen@rm.dk
        • Hoofdonderzoeker:
          • Louise T Henriksen, MD, PhD
      • Copenhagen, Denemarken, 2100
        • Werving
        • Rigshospitalet
        • Contact:
        • Hoofdonderzoeker:
          • Christine Dahl, Consultant, MD, PhD
      • Odense, Denemarken, 5000
        • Werving
        • Odense University Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Sebastian W Most-Mottelson, MD, PhD Student

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

6 jaar tot 27 jaar (Kind, Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Diagnosed and treated for a brain tumor during childhood or adolescence (0-≤18 years).
  2. Treated for a brain tumor during the previous 10 years.
  3. Age ≥6 years and <28 years at the start of the trial.
  4. Off therapy/active treatment for pediatric brain tumor (PBT) for 12 months at the start of the trial.
  5. No known signs of clinical or radiological tumor progression at last follow-up.
  6. Danish is the sole or primary language (enabling provision of validated assessment tools).
  7. Patient and family have provided consent for inclusion in the trial.
  8. Clinically significant fatigue based on the PedsQL MFS questionnaire at baseline, defined by a score ≥ 1 standard deviation below the normative mean.
  9. History of clinically relevant fatigue after treatment of PBT compared to estimated premorbid ability, as assessed from consultations in the childhood cancer outpatient clinics.

Exclusion Criteria:

  1. Any known contraindications to methylphenidate as outlined below:

    A) Hypersensitivity to the active substance or any excipients listed in the summary of product characteristics. B) Glaucoma. C) Pheochromocytoma. D) Hyperthyroidism. E) Mania. F) Psychosis. G) Anorexia nervosa. H) Current or previous severe depression. I) Suicidal behavior. J) Poorly controlled type 1 bipolar affective disorder. K) Antisocial or borderline personality disorder. L) Pre-existing cardiovascular disorders, including severe hypertension, heart failure, arterial occlusive disease, angina pectoris, hemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening cardiac arrhythmias and channelopathies. M) Pre-existing cerebrovascular disease, cerebral aneurysm, vascular abnormalities including vasculitis or stroke. N) Treatment with irreversible MAO inhibitors within the last 14 days and reversible MAO inhibitors within the last 24 hours.

  2. History of recent poorly controlled seizures.

  3. Complex tics or Tourette syndrome (including family history of tic disorder).

  4. Known diagnosis of Attention Deficit/Hyperactivity Disorder or Autism Spectrum Disorder.

  5. Known diagnosis of Full Scale Intelligence Quotient (FSIQ) of <50.

  6. Pregnancy. Participants known to be pregnant or breastfeeding at screening/registration will not be enrolled in the trial. All sexually active women of childbearing potential (WOCBP) must have a negative pregnancy test prior to the start of treatment. Acceptableeffective contraceptive must be used for the duration of the trial. No further testing is needed during trial, unless the participant suspects to have become pregnant.

  7. Concerns about family ability to safely store or administer MPH, or to report side effects appropriately/concerns about familial substance abuse.

  8. Concurrent use of opiods (ATC N02A) or benzodiazepines (ATC N05BA and N05CF).

  9. Simultaneously enrolled in another clinical trial investigating cancer-related fatigue with a pharmaceutical intervention.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Crossover-opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Methylphenidate, Then Placebo

Patients will receive treatment with methylphenidate tablets for 6 weeks, and then cross over to treatment with methylphenidate-matched placebo tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments.

10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally.

For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol.

10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally.

Dosage will follow the exact same principles as for the study drug (methylphenidate).

Experimenteel: Placebo, Then Methylphenidate

Patients will receive treatment with methylphenidate-matched placebo tablets for 6 weeks, and then cross over to treatment with methylphenidate tablets for an additional 6 weeks. A four week wash out period is incorporated between treatments.

10 mg methylphenidate tablets with a scoreline. Tablets will be administered orally.

For children aged 6-12, a daily dose of 5 mg x 2 will be administered during the first week with an increase in dose to 10 mg x 2 in the second week. For adolescents and adults above 12 years of age, the same starting dose will be used as for children, with weekly incremental increases up to a maximum of 15 mg x 2 daily in the third week. In case of potential toxicity events during study, dosage of methylphenidate can be modified according to protocol.

10 mg methylphenidate-matched placebo tablets with a scoreline. Tablets will be administered orally.

Dosage will follow the exact same principles as for the study drug (methylphenidate).

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
PedsQL Multidimensional Fatigue Scale (MFS)
Tijdsspanne: At baseline, at Week 6, Week 16, and Week 20 (follow-up).

Changes in patient self-reported fatigue (participants above 18 years of age) or parent proxy-reported fatigue (participants between 6-17 years of age) from baseline to week 6 of MPH or placebo treatment as measured by the PedsQL Multidimensional Fatigue Scale (MFS).

At baseline, at Week 6, Week 16, and Week 20 (follow-up).

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
PedsQL Multidimensional Fatigue Scale (MFS)
Tijdsspanne: At baseline, at Week 6, Week 16, and Week 20 (follow-up).

Changes from baseline in self-reported fatigue (participants aged 6-17 years of age) measured by the PedsQL MFS.

At baseline, at Week 6, Week 16, and Week 20 (follow-up).
Behaviour Rating Inventory of Executive Function (BRIEF)
Tijdsspanne: At baseline, at Week 6, and Week 16.

Changes from baseline in self and parent-reported executive function measured by the BRIEF-2 or BRIEF-V questionnaire.

At baseline, at Week 6, and Week 16.
Connor's Continuous Performance Test (CPT) Online Suite
Tijdsspanne: At baseline, at Week 6, and Week 16.

Changes from baseline in digital measures of sustained attention and executive function. CPT-3 and K-CPT-2 will be used.

At baseline, at Week 6, and Week 16.
Wechsler Coding
Tijdsspanne: At baseline, at Week 6, and Week 16.

Changes from baseline in processing speed. Coding module from Wechsler Intelligence Scale for Children Fifth Edition (WISC-V) or Wechsler Adult Intelligence Scale Fifth Edition (WAIS-V) depending on age of participant.

At baseline, at Week 6, and Week 16.
Wechsler Digit Span
Tijdsspanne: At baseline, at Week 6, and Week 16.

Changes from baseline in working memory. Coding module from WISC-V or WAIS-V depending on age of participant.

At baseline, at Week 6, and Week 16.
PedsQL Generic Core Scales
Tijdsspanne: At baseline, at Week 6, and Week 16.

Changes from baseline in self and parent-reported measures of Health Related Quality of Life.

At baseline, at Week 6, and Week 16.
Accelerometry (Axivity AX3)
Tijdsspanne: Accelerometry will be performed for a duration of 1 week during week 4-6 and week 14-16 during the study arm.

Time spent within different activity domains and sleep-wake patterns measured by accelerometry. Axivity AX3 accelerometers will be used.

Accelerometry will be performed for a duration of 1 week during week 4-6 and week 14-16 during the study arm.
Barkley's Stimulant Side Effect Rating Scale (SSERS)
Tijdsspanne: At baseline, Week 2, Week 3, Week 4, Week 6, Week 10, Week 12, Week 13, Week 14, Week 16, and Week 20 (follow-up)..

Changes from baseline in self and parent-reported side-effects. A modified version of SSERS with 21 items customized to Danish practice will be used.

At baseline, Week 2, Week 3, Week 4, Week 6, Week 10, Week 12, Week 13, Week 14, Week 16, and Week 20 (follow-up)..

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Mathias Rathe, Consultant, MD, PhD, Odense University Hospital

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

2 september 2025

Primaire voltooiing (Geschat)

1 december 2029

Studie voltooiing (Geschat)

1 december 2029

Studieregistratiedata

Eerst ingediend

27 november 2024

Eerst ingediend dat voldeed aan de QC-criteria

25 maart 2025

Eerst geplaatst (Werkelijk)

1 april 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

3 november 2026

Laatste update ingediend die voldeed aan QC-criteria

30 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren